Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Losmapimod - Fulcrum Therapeutics/GlaxoSmithKline

Drug Profile

Losmapimod - Fulcrum Therapeutics/GlaxoSmithKline

Alternative Names: 856553; FTX-1821; GS856553; GSK 856553; GW 856553; GW856553X

Latest Information Update: 21 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Fulcrum Therapeutics; GlaxoSmithKline
  • Class Anti-inflammatories; Antiasthmatics; Antirheumatics; Cardiovascular therapies; Small molecules
  • Mechanism of Action DUX4 protein inhibitors; P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute coronary syndromes
  • Phase II Chronic obstructive pulmonary disease; Facioscapulohumeral muscular dystrophy; Focal segmental glomerulosclerosis
  • No development reported Inflammation
  • Discontinued Atherosclerosis; Dyslipidaemias; Major depressive disorder; Neuropathic pain; Rheumatoid arthritis

Most Recent Events

  • 04 Oct 2019 Preliminary pharmacokinetics and adverse events data from a phase-I trial in Facioscapulohumeral muscular dystrophy released by Fulcrum Therapeutics
  • 26 Aug 2019 Fulcrum Therapeutics initiates a phase-I trial for Facioscapulohumeral muscular dystrophy and healthy volunteers before August 2019 (PO)
  • 26 Aug 2019 Phase-II clinical trials in Facioscapulohumeral muscular dystrophy in Netherlands (PO) (NCT04004000)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top